drugset / Trial / NCT01706679
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
Timeline
- Start
- 2012-10
- Primary completion
- 2013-02
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ATX-101 | Peptide | 10 mg/ml | — |
| Comparator | ATX-101 | Peptide | 20 mg/ml | — |
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
Indications
No indication recorded.